Cytokinetics (CYTK) Profit After Tax (2010 - 2026)

Cytokinetics (CYTK) has reported Profit After Tax for 17 consecutive years, with -$208.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Profit After Tax fell 29.06% year-over-year to -$208.3 million; the TTM figure through Mar 2026 stood at -$831.3 million (down 34.45% YoY), while the FY2025 annual figure was -$786.7 million, down 34.0% from the prior year.
• Profit After Tax fell to -$208.3 million in Q1 2026 per CYTK's latest filing, from -$182.4 million in the prior quarter.
• Across five years, Profit After Tax topped out at -$19.8 million in Q2 2022 and bottomed at -$306.2 million in Q3 2025.
• Historically, Profit After Tax has averaged -$147.0 million across 5 years, with a median of -$136.9 million in 2023.
• Annual changes were most pronounced in 2022 — Profit After Tax surged 67.8% — and 2023, when it plunged 549.03%.
• Cytokinetics' Profit After Tax stood at -$135.4 million in 2022, then slipped by 1.1% to -$136.9 million in 2023, then slipped by 11.77% to -$153.0 million in 2024, then declined by 19.23% to -$182.4 million in 2025, then fell by 14.16% to -$208.3 million in 2026.
• Business Quant data shows CYTK's Profit After Tax at -$208.3 million in Q1 2026, -$182.4 million in Q4 2025, and -$306.2 million in Q3 2025.